The COVID-19 pandemic impacts the hematology practice Intensive chemotherapies for high-grade lymphomas and acute leukemias, multiple myeloma treatments and most hematopoietic stem cell transplantations should be performed as usual Low-grade lymphomas should only be treated when strictly indicated, maintenance can be postponed Other myeloid neoplasia and their therapies cause imunosupression;dose adjustment is recommended but no brisk stopping Sickle cell anemia patients are highly succeptible to severe COVID-19 course Thrombocytopenia and procoagulant state are associated with severe courses of COVID-19, requiring an individualized therapy No data indicate a risk of SARS-CoV-2 transmission through blood product transfusion